Hans Christian Hagedorn
Co-founder 1923Background
Hans Christian Hagedorn was a pioneering Danish physician who co-founded the Nordisk Insulinlaboratorium in 1923. His defining moment was the development of the first prolonged-acting insulin formulations, which transformed insulin from a life-saving but short-acting emergency treatment into a manageable chronic therapy. This decision established the company's long-term philosophy of focusing on peptide chemistry and formulation science to improve patient compliance.
Role at Novo Nordisk A/S
Novo Nordisk possesses a historic, personal, and scientifically competitive founding story, rooted entirely in a Nobel Prize-winning discovery and defined by a bitter rivalry between two brilliant Danish scientists that lasted for over 60 years. The foundational origins of the company trace back to 1922 in Copenhagen, Denmark. August Krogh (a brilliant, Nobel Prize-winning professor at the University of Copenhagen) and his wife Marie Krogh (a respected medical doctor who had recently been tragically diagnosed with Type 2 diabetes) traveled to America. They heard exciting reports that researchers at the University of Toronto had extracted life-saving insulin. Krogh secured the exclusive rights to produce insulin in Scandinavia. He returned to Denmark and partnered with Dr. Hans Christian Hagedorn to found the Nordisk Insulinlaboratorium in 1923. Their foundational masterstroke was heavily improving the crude Canadian extraction process, saving the lives of sick Danish patients. However, the defining corporate drama occurred immediately. They had hired a brilliant, intensely ambitious pharmacist named Harald Pedersen (and his engineer brother Thorvald) to design the extraction machinery. In 1924, a bitter, irreconcilable personal dispute erupted. The Pedersen brothers were fired. enraged but knowledgeable, the brothers founded their own rival company (Novo Terapeutisk Laboratorium) just a few miles away. For over 60 intense years, Novo and Nordisk fought an aggressive, corporate war, constantly out-innovating each other in advanced diabetes care. The defining conclusion occurred in 1989, when the two entrenched rivals finally executed a historic mega-merger to form Novo Nordisk, uniting their expertise to form the undisputed global titan of modern metabolic medicine.